Two clinical trials for cancer were recently halted for the best possible reason; the drugs worked so well that it would be unethical to continue. One trial was for melanoma and the other was for lung cancer, but the drug-target was the same: Programmed cell death protein 1 (PD-1).
PD-1 is a protein that inhibits responses from T cells. Cancer often takes advantage of the PD-1 pathway to prevent a productive immune response that would otherwise kill the cancer. The drugs in both the clinical trials are antibodies that bind to PD-1, thus preventing cancer-mediated inhibition of the immune response. As this is a general mechanism that cancer uses to evade the immune system, it will likely be effective at treating other forms of cancer besides melanoma and lung cancer. Also, since the drugs are targeting T cells and not the cancer directly, resistance will not develop as easily.
http://pipeline.corante.com/archives/2015/04/17/stopped_for_efficacy_again.php
http://pipeline.corante.com/archives/2015/03/24/the_best_way_to_halt_a_clinical_trial.php
https://en.wikipedia.org/wiki/Programmed_cell_death_1
We looked around briefly and also found:
http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm412802.htm
http://www.reuters.com/article/2015/03/24/us-merck-melanoma-idUSKBN0MK1FO20150324
(Score: 2, Disagree) by Mr Big in the Pants on Saturday April 18 2015, @11:20PM
It was unethical to continue depriving a small handful of them of drugs.
A nice thought but you can bet this will priced such that it will be depriving MILLIONS and MILLIONS of people of the drug until the patent wears off. And that is when is finally comes out.
Yet another corrupt system trying to pretend they are doing good.
(Score: 3, Touché) by Mr Big in the Pants on Sunday April 19 2015, @03:36AM
You can disagree all you want. Its still true.